SRR12475125
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.400
- CHOLESTEROL_HOMEOSTASIS+0.310
- HEDGEHOG_SIGNALING+0.310
- GLYCOLYSIS+0.300
- NOTCH_SIGNALING+0.290
- MYC_TARGETS_V2+0.240
- ESTROGEN_RESPONSE_LATE+0.230
- WNT_BETA_CATENIN_SIGNALING+0.230
- ESTROGEN_RESPONSE_EARLY+0.190
- MTORC1_SIGNALING+0.170
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.480
- ALLOGRAFT_REJECTION-0.460
- INTERFERON_ALPHA_RESPONSE-0.440
- IL6_JAK_STAT3_SIGNALING-0.400
- TNFA_SIGNALING_VIA_NFKB-0.390
- INFLAMMATORY_RESPONSE-0.380
- PROTEIN_SECRETION-0.380
- COMPLEMENT-0.330
- KRAS_SIGNALING_UP-0.290
- APOPTOSIS-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-39-5027-01A-21R-1820-07 | — | cohortSQ2 | 0.835 |
| 2 | 5d2d4263-d17d-424f-9c82-bf665306d71f | — | — | 0.803 |
| 3 | MNG538 | — | — | 0.794 |
| 4 | cc1c7e4b-89a0-4d94-b9e5-293c2eacadd9 | — | — | 0.794 |
| 5 | 124c158a-8435-4f81-b84e-89ccc4bb53f1 | — | — | 0.784 |
| 6 | DRR168602 | — | — | 0.783 |
| 7 | SRR2669446 | — | — | 0.782 |
| 8 | add96e53-1114-4364-979b-641665d16629 | — | — | 0.772 |
| 9 | R1 | — | — | 0.770 |
| 10 | TCGA-UF-A71A-01A-22R-A34R-07 | — | — | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.070 | Inavolisib | — uncovered |